Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 2167-2179

  Chodick, Gabriel ^a,b   Shalev, Varda ^a,b   Gerber, Yariv ^b   Heymann, Anthony D ^a,b   Silber, Haim ^a,b   Simah, Virginia ^a   Kokia, Ehud ^a  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

adherence; dyslipidemia; persistence; statins

Indexed keywords

CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; ISRAEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS; DRUG COSTS; EMIGRANTS AND IMMIGRANTS; FEMALE; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; ISRAEL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OBESITY; ORGANIZATIONS, NONPROFIT; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SIMVASTATIN; SOCIAL CLASS; TIME FACTORS;

EID: 57649211987     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.11.012     Document Type: Article

References (49)

1. Shepherd J., Cobbe S.M., Ford I., et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
2. Sachs F.M., Pfeffer M.A., Moye L.A., et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
3. Genest J., Frohlich J., Fodor G., McPherson R., and for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update [published correction appears in CMAJ. 2003;169:1149]. CMAJ 169 (2003) 921-924
4. Blackburn D.F., Dobson R.T., Blackburn J.L., et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study. Can J Cardiol 21 (2005) 485-488
5. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27 (2006) 1153-1158
6. Kulkarni S.P., Alexander K., Lytle B., et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 151 (2006) 185-191
7. Simpson E., Beck C., Richard H., et al. Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence. Am Heart J 145 (2003) 438-444
8. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
9. Kopjar B., Sales A.E., Pineros S.L., et al. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 92 (2003) 1106-1108
10. Muhlestein J.B., Horne B.D., Bair T.L., et al. Usefulness of in-hospital prescription of statin agents after angio graphic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 87 (2001) 257-261
11. Andrade S.E., Walker A.M., Gottlieb L.K., et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 332 (1995) 1125-1131
12. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
13. Larsen J., Andersen M., Kragstrup J., and Gram L.F. High persistence of statin use in a Danish population: Com pliance study 1993-1998. Br J Clin Pharmacol 53 (2002) 375-378
14. Benner J.S., Tierce J.C., Ballantyne C.M., et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmaco Economics 22 Suppl 3 (2004) 13-23
15. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59 (2005) 564-573
16. Simons L.A., Levis G., and Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-211
17. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 279 (1998) 1458-1462
18. Abughosh S.M., Kogut S.J., Andrade S.E., et al. Persistence with lipid-lowering therapy: Influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 10 (2004) 404-411
19. Lachaine J., Rinfret S., Merikle E.P., and Tarride J.E. Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data. Am Heart J 152 (2006) 164-169
20. van der Elst M.E., Bouvy M.L., de Blaey C.J., and de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis. Clin Ther 27 (2005) 1806-1814
21. Catalan V.S., and LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 3 (2000) 417-426
22. Valuck R.J., Williams S.A., MacArthur M., et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 25 (2003) 2936-2957
23. Eriksson M., HÅdell K., Holme I., et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care. J Intern Med 243 (1998) 373-380
24. Hiatt J.G., Shamsie S.G., and Schectman G. Discontinuation rates of cholesterol-lowering medications: Implications for primary care. Am J Manag Care 5 (1999) 437-444
25. Gislason G.H., Rasmussen J.N., Abildstrøm S.Z., et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 116 (2007) 737-744
26. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 50 (1997) 105-116
27. Vrijens B., Belmans A., Matthys K., et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 15 (2006) 115-121
28. Heymann A.D., Chodick G., Kramer E., et al. Pemphigus variant associated with penicillin use: A case-cohort study of 363 patients from Israel. Arch Dermatol 143 (2007) 704-707
29. Shalev V., Chodick G., Bialik M., et al. In a population-based cohort of diabetes patients, men and women had similar risks for all-cause mortality. J Clin Epidemiol 60 (2007) 86-93
30. Caetano P.A., Lam J., and Morgan S.G. Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther 28 (2006) 1411-1424 discussion 1410
31. 1995 Census of Population and Housing (1998), Israel Central Bureau of Statistics, Jerusalem, Israel
32. Chodick G., Heymann A.D., Shalev V., and Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 18 (2003) 1143-1146
33. D'Hoore W., Bouckaert A., and Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 49 (1996) 1429-1433
34. Meyer J.W., Schultz J.S., O'Donnell J.C., et al. Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health 8 (2005) 601-612
35. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82:128]. Am J Cardiol 81 (1998) 582-587
36. Dujovne C.A., Knopp R., Kwiterovich P., et al., for the Cerivastatin Study Group. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1030 hypercholesterolemic patients. Mayo Clin Proc 75 (2000) 1124-1132
37. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 32 (1972) 187-220
38. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
39. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
40. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. The Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
41. Deambrosis P., Saramin C., Terrazzani G., et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 63 (2007) 197-203
42. Caspard H., Chan A.K., and Walker A.M. Compliance with a statin treatment in a usual-care setting: Retrospec tive database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 27 (2005) 1639-1646
43. Mosca L., Ferris A., Fabunmi R., Robertson R.M., and for the American Heart Association. Tracking women's awareness of heart disease: An American Heart Association national study. Circulation 109 (2004) 573-579
44. Christian A.H., Mochari H.Y., and Mosca L.J. Coronary heart disease in ethnically diverse women: Risk perception and communication. Mayo Clinic Proc 80 (2005) 1593-1599
45. Gibson T, Mark T, Axelsen K, et al. The effects of statin (HMG-CoA reductase inhibitor) copayments and statin adherence on medical care and expenditures. Presented at: ISPOR 11th Annual International Meeting; May 20-24, 2006; Philadelphia, Pa.
46. Rasmussen J.N., Gislason G.H., Rasmussen S., et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health 61 (2007) 1091-1097
47. Brookhart M.A., Patrick A.R., Dormuth C., et al. Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 166 (2007) 348-354
48. Demissie K., Hanley J.A., Menzies D., et al. Agreement in measuring socioeconomic status: Area-based versus individual measures. Chronic Dis Can 21 (2000) 1-7
49. Krieger N., Chen J.T., Waterman P.D., et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: Does the choice of area-based measure and geographic level matter?: The Public Health Disparities Geocoding Project. Am J Epidemiol 156 (2002) 471-482